Page last updated: 2024-08-24

triazoles and Anemia, Cooley's

triazoles has been researched along with Anemia, Cooley's in 157 studies

Research

Studies (157)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	30 (19.11)	29.6817
2010's	118 (75.16)	24.3611
2020's	9 (5.73)	2.80

Authors

Authors	Studies
Cheng, K; Greenway, A; Kaplan, Z; Wu, S; Zargari, A	1
Babu, T; Panachiyil, GM; Ravi, MD; Sebastian, J	1
Ahmed, J; Moeed, A; Naeem, U; Rais, H; Saleem, A; Shuja, SH; Waqar, E	1
Baker, Z; Dillon, H; Pena, A; Sparks, S; Syed, H; Wang, Y	1
Buaboonnam, J; Narkbunnam, N; Phuakpet, K; Pongtanakul, B; Sanpakit, K; Takpradit, C; Vathana, N; Viprakasit, V	1
Allò, M; Campisi, S; Casale, M; Cassinerio, E; Cattoni, A; De Michele, E; Di Concilio, R; Ferrara, F; Forni, GL; Ladogana, S; Lazzarino, AI; Marcon, A; Notarangelo, LD; Origa, R; Pasquali, D; Peluso, A; Perrotta, S; Picariello, S; Poggi, M; Putti, MC; Quarta, A; Renni, R; Roberti, D; Sau, A; Serra, M; Sportelli, F; Sturiale, P; Tartaglione, I	1
Aboobacker, FN; Abraham, A; Dixit, G; George, B; Korula, A; Lakshmi, KM; Mathews, V; Srivastava, A	1
Etemadfar, P; Ghaedi, M; Ghatee, MA; Moghaddam, AG; Omidifar, N; Rad, F; Zardkhoni, SZ	1
Bintoro, SUY; Qatrunnada, H; Wahyuni, S	1
Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L	1
Akay, C; Bayhan, T; Çırak, E; Eker, İ; Erdem, O; Gümrük, F; Gürsel, O; Karabulut, E; Ünal, Ş	1
Antonucci, R; Asara, MA; Caggiari, S; Capobianco, G; Dessole, S; Dore, F; Fozza, C; Monti, A; Vacca, N; Zaccheddu, F	1
Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E	1
Doery, JC; Kaplan, Z; Kerr, PG; Yii, E	1
Doree, C; Estcourt, LJ; Fisher, SA; Fortin, PM; Hopewell, S; Madgwick, KV; Trivella, M	1
Cappellini, MD; Caruso, V; Chiavilli, F; Commendatore, F; Forni, GL; Galanello, R; Longo, F; Mulas, S; Musallam, KM; Piga, A; Quarta, G	1
Ammirabile, M; Casale, M; Cinque, P; Costantini, S; Di Matola, T; Filosa, A; Prossomariti, L; Ricchi, P; Spasiano, A	1
Akianidis, V; Christoulas, D; Karavas, A; Komninaka, V; Terpos, E; Voskaridou, E	1
Bianchetti, MG; Brazzola, P; Dell'Orto, VG	1
Bina, P; Cossa, S; Danjou, F; Defraia, E; Dessì, C; Foschini, ML; Galanello, R; Leoni, G; Matta, G; Morittu, M; Origa, R	1
Haghpanah, S; Karimi, M; Zahedi, Z; Zarei, T	1
Alizadeh, S; Bamedi, T; Dorgalaleh, A; Jahantigh, A; Naderi, M; Sadeghi-Bojd, S; Tabibian, S; Valeshabad, AK	1
Abdollah Gorji, F; Alavi, S; Arzanian, MT; Ebadi, M; Ghazizadeh, F; Shamsian, B	1
Aydinok, Y; Belhoul, KM; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, Y; Lawniczek, T; Pennell, DJ; Piga, A; Porter, JB; Weisskopf, M; Yesilipek, A; Zhang, Y	1
Economou, M; Garypidou, V; Gombakis, N; Kargioti, A; Neokleous, N; Papachristou, F; Teli, A; Theodoridou, S; Vakalopoulou, S; Vlachaki, E; Vyzantiadis, TA	1
Abuhandan, M; Aycicek, A; Koc, A	1
Coates, TD	1
Cappellini, MD; Cassinerio, E; Duca, L; Fraquelli, M; Orofino, N; Poggiali, E; Roghi, A; Zanaboni, L	1
Brown, M; Niv, Y; Pazgal, I; Perets, TT; Rachmilewitz, E; Stark, P	1
Cappellini, MD; Castiglioni, C; Longo, F; Origa, R; Piga, A; Pinna, F; Roggero, S; Zappu, A	1
Chan, GC; Cheuk, DK; Chiang, AK; Dee, CM; Ha, SY	1
Al-Momen, A; Aleem, A; Algahtani, F; Alsaleh, K; Iqbal, Z; Shakoor, Z	1
A Bed, MA; Al Khawaldeh, OA; Al Tawarah, YM; Al-Kloub, MI; Froelicher, ES	1
Amendola, G; Casale, M; Cinque, P; Citarella, S; De Michele, E; Della Rocca, F; Filosa, A; Nobili, B; Palmieri, F; Perrotta, S; Pugliese, U; Ragozzino, A; Tartaglione, I	1
Aydinok, Y; El-Beshlawy, A; Elalfy, M; Habr, D; Kilinç, Y; Lai, YR; Musallam, KM; Pennell, DJ; Piga, A; Porter, JB; Shen, J; Yesilipek, A	1
Bouillaud, E; Cappellini, MD; Forni, GL; Fracchia, S; Habr, D; Hirschberg, R; Lai, ME; Piga, A; Wegener, A	1
Cappellini, MD; Cassinerio, E; Consonni, D; Giuditta, M; Orofino, N; Pedrotti, P; Poggiali, E; Roghi, A; Zanaboni, L	1
Genc, GE; Gumuslu, S; Kupesiz, A; Kurtoglu, E; Ozturk, Z	1
Adly, AM; Elalfy, MS; Elhenawy, YI; Samir, A; Tony, S; Wali, Y	1
Arandi, N; Ashrafi, A; Eatemadfar, P; Haghpanah, S; Karimi, M; Radwan, AH; Safaei, S; Taher, AT; Zahedi, Z; Zarei, T	1
Attri, SV; Bansal, D; Bhatia, P; Marwaha, RK; Totadri, S; Trehan, A	1
Erman, A; Feige Gross Nevo, R; Gafter, U; Gafter-Gvili, A; Milo, G; Pazgal, I; Shpilberg, O; Stark, P	1
Chiang, PH; Kuo, PH; Lai, CW; Lin, KH; Lu, MY; Wang, N; Wu, TH; Wu, WH	1
Ansari, S; Arandi, N; Azarkeyvan, A; Bordbar, M; Haghpanah, S; Karimi, M; Safaei, S	1
Agapidou, A; Boura, P; Klonizakis, P; Mavroudi, M; Spanos, G; Vetsiou, E; Vlachaki, E	1
Genc, GE; Gumuslu, S; Kupesiz, A; Ozturk, Z	1
Hagag, AA; Hamam, MA; Hazaa, SM; Taha, OA	1
Chang, HH; Jou, ST; Lin, DT; Lin, KH; Lu, MY; Peng, SS; Yang, YL	1
El Rassi, F; Saliba, AN; Taher, AT	1
Aygener, N; Eyigor, H; Kurtoglu, E; Osma, U; Yilmaz, MD	1
Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E	1
Corpino, M; Dessì, C; Foschini, ML; Leoni, G; Moi, P; Morittu, M; Origa, R; Zappu, A	1
Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V	1
Angelucci, E; Pilo, F	1
Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A	1
Allegra, S; Cusato, J; D'Avolio, A; De Francia, S; Massano, D; Piga, A; Pirro, E	2
Arnon, R; Chu, J; Ramaswami, A; Rosen, DJ; Wistinghausen, B	1
Avazpour, A; Badie, A; Haghpanah, S; Karimi, M; Toosi, F	1
Abbas, HA; Cappellini, MD; Inati, A; Kahale, M; Koussa, S; Musallam, KM; Nasr, TA; Porter, JB; Sbeiti, N; Taher, AT	1
Barnes, SL; Bowden, D; Charles, S; Davies, D; Davies, GI	1
Bayhan, T; Gümrük, F; Karabulut, E; Küçüker, H; Tutal, AD; Ünal, Ş; Ünlü, O	1
Allegra, S; Arduino, A; Cusato, J; D'Avolio, A; De Francia, S; Longo, F; Massano, D; Piga, A; Pirro, E	1
Chiang, PH; Kuo, PH; Lin, KH; Lin, TH; Lu, MY; Wang, N; Wu, TH; Wu, WH	1
Bentley, A; Caruso, V; Cuccia, L; D'Ascola, DG; Filosa, A; Frizziero, L; Hanif, A; Meloni, A; Pepe, A; Putti, MC; Rossi, G; Spasiano, A	1
Chandra, J; Dhingra, B; Jain, R; Mahto, D; Parakh, N; Sharma, S	1
Ford, JM; Rojkjaer, L	1
Mahmoud, A; Musallam, KM; Taher, AT	1
Hamdan, MA; Hayek, M; Ishaqi, MK; Jamil, A; Khanani, MF; Shamsi, A; Trad, O	1
Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Hmissi, A; Kriemler-Krahn, U; Taher, A	1
Daar, S; Habr, D; Hmissi, A; Kriemler-Krahn, U; Nick, H; Pathare, A; Taher, A	1
Ahmad, F; Amani, M; Babaahmadi, A; Divsalar, A; Farzami, B; Hakimelahi, GH; Kamarie, M; Karimian, K; Moosavi-Movahedi, AA; Mousavy, SJ; Poursasan, N; Riazi, GH; Saboury, AA; Shafiee, A; Tsai, FY	1
Daar, S; Pathare, A; Taher, A	1
Chang, JS; Chiou, SS; Hsiao, CC; Hung, GY; Peng, CT; Wang, LY; Wang, SC; Wu, KH	1
Christoulas, D; Delaki, EE; Douskou, M; Papadakis, M; Plata, E; Terpos, E; Voskaridou, E	1
Fibach, E; Prus, E	1
Aloizos, G; Kikilas, A; Papadopoulos, N; Tapinis, P; Vasiliki, A	1
Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Sutcharitchan, P; Taher, A; Viprakasit, V	1
Telfer, P	1
Bauters, T; de Moerloose, B; Hunninck, K; Mondelaers, V; Robays, H	1
Ammirabile, M; Cinque, P; Costantini, S; Di Matola, T; Prossomariti, L; Ricchi, P; Spasiano, A	1
Bruin, GJ; Glaenzel, U; Hazell, K; Porter, JB; Sechaud, R; Waldmeier, F; Warrington, S	1
Delaporta, P; Goussetis, E; Hantzi, E; Kattamis, A; Ladis, V; Margeli, A; Papassotiriou, I; Sergounioti, A	1
Athanassiou-Metaxa, M; Economou, M; Papachristou, F; Printza, N; Teli, A; Tsatra, I; Tzimouli, V	1
Borsellino, Z; Cuccia, L; Gagliardotto, F; Marocco, MR; Ruffo, GB; Tarantino, R	1
Coates, TD; Giardina, P; Glynos, T; Harmatz, P; Kang, BP; Paley, C; Thompson, A; Wood, JC	3
Al Jefri, A; Al Zir, K; Baladi, JF; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Rofail, D; Taher, A	1
Balocco, M; Carrara, P; Forni, GL; Pinto, V	1
Berdoukas, V; Berdoussi, E; Chouliaras, G; Kattamis, C; Ladis, V; Moraitis, P; Zannikos, K	1
Karasu, G; Kazik, M; Ozturk, Z; Uygun, V; Yesilipek, MA	1
Aytac, S; Cetin, M; Eldem, G; Gumruk, F; Hazirolan, T; Kuskonmaz, B; Uckan, D; Unal, S	1
Christoulas, D; Dimopoulou, M; Douskou, M; Mpoutou, E; Plata, E; Sioni, A; Terpos, E; Voskaridou, E	1
Porter, JB	1
Barzilai-Birenbaum, S; Krause, I; Pazgal, I; Stark, P; Tamary, H; Yacobovich, J; Yaniv, I	1
Bisconte, MG; Capra, M; Caruso, V; Cianciulli, P; Filosa, A; Lippi, A; Lombardi, M; Maggio, A; Malaventura, C; Meloni, A; Midiri, M; Missere, M; Pepe, A; Pitrolo, L; Positano, V; Prossomariti, L; Putti, MC; Quarta, A; Romeo, MA; Rossi, G	1
Berdousi, H; Gotsis, E; Kattamis, A; Ladis, V	1
Aydinok, Y; Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, MS; Habr, D; Ibrahim, H; Kattamis, A; Li, CK; Pennell, DJ; Porter, JB; Roubert, B; Smith, G; Taher, A; Viprakasit, V	2
Chang, HH; Chang, TT; Chiou, SS; Jou, ST; Liao, YM; Lin, DT; Lin, KH; Lin, PC; Lu, MY; Yang, YL	1
Cheng, CH; Lo, FS; Wei, HY; Yang, CP	1
Eldem, G; Gumruk, F; Hazirolan, T; Unal, S	1
Abdin, IA; Ebeid, FS; El Safy, UR; Elalfy, MS; Ibrahim, AS; Salem, DS	1
Drosou, M; Servos, P; Vini, D	1
Chandra, J; Chaudhary, H; Dutta, AK; Pemde, H; Singh, V	1
Cinque, P; Costantini, S; Di Matola, T; Prossomariti, L; Ricchi, P; Spasiano, A	1
Bechtel, H; Kashtan, CE; Neglia, JP; Rheault, MN	1
Bekiari, E; Chatzinikolaou, K; Klonizakis, F; Tsapas, A; Vlachaki, E	1
Abu-Taleb, A; Alawadi, AH; Garadah, TS; Kassab, S; Mahdi, N; Shoroqi, I	1
Christoulas, D; Terpos, E; Voskaridou, E	1
Chaiyakunapruk, N; Luangasanatip, N; Upakdee, N; Wong, P	1
Agaoglu, L; Aydinok, Y; Bejaoui, M; Canatan, D; Cappellini, MD; Capra, M; Clark, J; Cohen, A; Dong, V; Drelichman, G; Economou, M; Fattoum, S; Griffel, L; Kattamis, A; Kilinc, Y; Perrotta, S; Piga, A; Porter, JB	1
Al Jefri, A; Al Zir, K; Daar, S; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Roubert, B; Taher, A	1
Al Jefri, A; Al Zir, K; Daar, S; El-Ali, A; El-Beshlawy, A; Elalfy, MS; Habr, D; Kriemler-Krahn, U; Roubert, B; Taher, A	1
Abbate, G; Anastasi, S; Caruso, V; De Sanctis, V; Giovannini, M; Lisi, R	1
Brissot, P; Cappellini, MD; Deugnier, Y; Giannone, V; Griffel, L; Porter, JB; Ropert, M; Turlin, B; Zhang, Y	1
Chen, GF; Chen, JJ; Gao, HY; Li, CG; Li, Q	1
Aloj, G; Bonifazi, F; Cappellini, MD; Cassarà, F; Ceci, A; Cianciulli, P; Filosa, A; Fucharoen, S; Gluud, C; Grady, RW; Harmatz, P; Iacono, A; Kattamis, A; Maggio, A; Porter, JB; Prossomariti, L; Vitrano, A; Wood, J	1
Adams, PC	1
El-Beshlawy, A; Evangeli, M; Porter, JB	1
Bansal, D; Marwaha, RK; Panigrahi, I; Vaidya, PC	1
Panderi, I; Pligoropoulou, H; Vonaparti, A	1
Karakukcu, C; Karakukcu, M; Ozdemir, MA; Patiroglu, T; Tang, PH; Torun, YA; Unal, E	1
Brevi, F; Cappellini, MD; Cassinerio, E; Graziadei, G; Milazzo, A; Pattoneri, P; Pedrotti, P; Roghi, A; Zanaboni, L	1
Dessi, C; Galanello, R; Giardina, PJ; Grady, RW; Kleinert, DA; Randolph, RE	1
Agapidou, A; Economou, M; Efthimia, V; Neokleous, N; Perifanis, V; Teli, A; Vetsiou, E	1
Chandiwana, D; Karnon, J; Tolley, K; Vieira, J	1
Aylak, F; Canatan, D; Erdoğan, E; Ormeci, AR; Vural, H	1
Ruivard, M	1
Dua, V; Oberoi, J; Sachdeva, A; Yadav, SP	1
Javanbakht, M; Karimi, M; Keshtkaran, A; Mashayekhi, A; Nuri, B; Salavati, S	1
Balocco, M; Forni, GL; Frassoni, F; Musallam, KM; Musso, M; Piaggio, G; Podestà, M; Pozzi, S; Rosa, A	1
Kurtoglu, E; Uygun, V	1
Al Rawas, A; Bashir, W; Pathare, A; Tony, S; Wali, Y; Zachariah, M	1
Acklin, P; Faller, B; Hauffe, S; Jin, Y; Lattmann, R; Nick, H; Schnebli, HP; Sergejew, T; Thomas, H; Wong, A	1
Alberti, D; Anderson, JR; Giardina, PJ; Grady, RW; Krebs-Brown, AJ; Nathan, DG; Neufeld, EJ; Nisbet-Brown, E; Olivieri, NF; Séchaud, R; Sizer, KC	1
Alberti, D; Bigler, H; Galanello, R; Piga, A; Rouan, MC; Séchaud, R	1
Cabantchik, ZI; Hershko, CM; Konijn, AM; Link, GM	1
Galanello, R	1
Agaoglu, L; Alberti, D; Athanassiou-Metaxa, M; Aydinok, Y; Bejaoui, M; Cappellini, MD; Capra, M; Coates, T; Cohen, A; Drelichman, G; Fattoum, S; Galanello, R; Giardina, P; Janka-Schaub, G; Kattamis, A; Kilinc, Y; Kourakli-Symeonidis, A; Magnano, C; Marks, P; Olivieri, N; Opitz, H; Perrotta, S; Piga, A; Porter, J; Ressayre-Djaffer, C; Thuret, I; Verissimo, M; Vermylen, C	1
Neufeld, EJ	1
Agarwal, MB	1
Alberti, D; Bordone, E; Cappellini, MD; Donato, G; Ford, JM; Forni, GL; Galanello, R; Hewson, N; Lavagetto, A; Opitz, H; Origa, R; Piga, A; Sechaud, R; Zanaboni, L; Zappu, A	1
Alberti, D; Belleli, R; Bertrand, Y; Bordone, E; Forni, GL; Foschini, ML; Galanello, R; Hewson, N; Lavagetto, A; Leoni, G; Longo, F; Maseruka, H; Piga, A; Sechaud, R; Zappu, A	1
Al-Fayoumi, S; Castillo, S; Chakraborti, T; Choudary, J; Frankewich, R; Kacuba, A; Pazdur, R; Rieves, D; Robie-Suh, K; Shashaty, G; Weiss, K	1
Barton, JC	1
Baladi, JF; Coates, TD; Delea, TE; Phatak, PD; Sofrygin, O; Thomas, SK	1
Rose, C	1
Abetz, L; Abish, S; Agaoglu, L; Baladi, JF; Bejaoui, M; Cappellini, MD; Cario, H; Coates, T; Ferster, A; Girot, R; Jeng, M; Lai, ME; Loggetto, S; Mangiagli, A; Opitz, H; Porter, J; Ressayre-Djaffer, C; Rofail, D; Strauss, G; Vichinsky, E; Watman, N; Zoumbos, N	1
Choudhry, VP; Naithani, R	1
Cohen, AR; Glimm, E; Porter, JB	1
Alberti, D; Alimena, G; Cappellini, MD; Cario, H; Cazzola, M; Cunningham, MJ; Debusscher, L; Della Porta, M; Ford, JM; Forni, GL; Galanello, R; Gathmann, I; Gattermann, N; Giardina, P; Greenberg, P; Jeng, M; Kwiatkowski, J; Maertens, J; Neufeld, EJ; Olivieri, N; Piga, A; Porter, J; Quarta, G; Rabault, B; Rose, C; Saglio, G; Soulières, D; Stadler, M; Tchernia, G; Vichinsky, E	1
Arpa, P; Azzolini, M; De Molfetta, V; Masera, G; Masera, N; Rescaldani, C; Tavecchia, L; Vimercati, C	1
Chan, GC; Cheung, YF; Ha, SY	1
Angelucci, E; Barosi, G; Camaschella, C; Cappellini, MD; Cazzola, M; Galanello, R; Marchetti, M; Piga, A; Tura, S	1
Alberti, D; Coates, T; Evans, P; Giardina, PJ; Harmatz, P; Holland, J; Kwiatkowski, JL; Macklin, EA; Neufeld, EJ; Olivieri, N; Porter, J; Vichinsky, E; Walter, PB	1

Reviews

11 review(s) available for triazoles and Anemia, Cooley's

Article	Year
No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2023, Volume: 30, Issue:1 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Ferritins; Hemoglobinopathies; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyridones; Triazoles	2023
Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. The Cochrane database of systematic reviews, 2018, 05-08, Volume: 5 Topics: Adolescent; Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Patient Compliance; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Triazoles	2018
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Expert review of hematology, 2016, Volume: 9, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Pregnancy; Pyridones; Triazoles	2016
Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Annals of the New York Academy of Sciences, 2016, Volume: 1368, Issue:1 Topics: Animals; Benzoates; beta-Thalassemia; Deferasirox; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Triazoles	2016
Update on survival in thalassemia major. Hemoglobin, 2009, Volume: 33 Suppl 1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Follow-Up Studies; Humans; Iron Chelating Agents; Pyridones; Survival Rate; Treatment Outcome; Triazoles	2009
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood cells, molecules & diseases, 2011, Oct-15, Volume: 47, Issue:3 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iron; Iron Chelating Agents; Liver; MEDLINE; Myocardium; Pyridones; Randomized Controlled Trials as Topic; Siderophores; Treatment Outcome; Triazoles; Ventricular Function	2011
[Iron chelating therapy in adults: How and when ?]. La Revue de medecine interne, 2013, Volume: 34, Issue:1 Topics: Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Myelodysplastic Syndromes; Myocardium; Pyridones; Siderophores; Triazoles	2013
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood, 2006, May-01, Volume: 107, Issue:9 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Clinical Trials as Topic; Costs and Cost Analysis; Deferasirox; Deferiprone; Deferoxamine; Heart Diseases; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles	2006
Exjade (ICL 670): A new oral iron chelator. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Deferasirox; Humans; Iron Chelating Agents; Models, Structural; Randomized Controlled Trials as Topic; Triazoles	2006
Chelation therapy for iron overload. Current gastroenterology reports, 2007, Volume: 9, Issue:1 Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles	2007
Current status of iron overload and chelation with deferasirox. Indian journal of pediatrics, 2007, Volume: 74, Issue:8 Topics: Benzoates; beta-Thalassemia; Clinical Trials as Topic; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Triazoles	2007

Trials

49 trial(s) available for triazoles and Anemia, Cooley's

Article	Year
Efficacy and Tolerability of Twice-Daily Dosing Schedule of Deferasirox in Transfusion-Dependent Paediatric Beta-Thalassaemia Patients: A Randomized Controlled Study. Journal of pharmacy practice, 2023, Volume: 36, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies; Thalassemia; Triazoles	2023
Heavy metal levels in patients with ineffective erythropoiesis. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2017, Volume: 56, Issue:4 Topics: Adolescent; Adult; Anemia, Dyserythropoietic, Congenital; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Erythropoiesis; Female; Humans; Male; Metals, Heavy; Triazoles	2017
A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox. Pediatric hematology and oncology, 2013, Volume: 30, Issue:8 Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Iron Overload; Kidney Diseases; Male; Metals; Prospective Studies; Triazoles	2013
Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran. Pediatric hematology and oncology, 2014, Volume: 31, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Drug Eruptions; Female; Ferritins; Gastrointestinal Diseases; Humans; Iran; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Myocardium; Prospective Studies; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood, 2014, Mar-06, Volume: 123, Issue:10 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Female; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Medication Adherence; Myocardium; Treatment Outcome; Triazoles; Troponin T; Young Adult	2014
Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience. Pediatrics international : official journal of the Japan Pediatric Society, 2014, Volume: 56, Issue:4 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Treatment Outcome; Triazoles	2014
Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox. American journal of hematology, 2014, Volume: 89, Issue:9 Topics: Adult; Benzoates; beta-Thalassemia; Breath Tests; Chi-Square Distribution; Deferasirox; Excipients; Female; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Lactose; Lactose Intolerance; Male; Middle Aged; Triazoles; Young Adult	2014
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Female; Ferritins; Hemosiderosis; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Medication Adherence; Prospective Studies; Stroke Volume; Transfusion Reaction; Triazoles; Young Adult	2014
Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major. American journal of hematology, 2014, Volume: 89, Issue:12 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Bone and Bones; Bone Density; Calcium; Chelation Therapy; Child; Child, Preschool; Deferasirox; Diabetes Mellitus; Diphosphonates; Female; Humans; Hypogonadism; Hypoparathyroidism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Puberty, Delayed; Retrospective Studies; Triazoles; Vitamin D	2014
Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American journal of hematology, 2015, Volume: 90, Issue:2 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Prospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles	2015
Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia. British journal of haematology, 2015, Volume: 168, Issue:6 Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Chelation Therapy; Creatinine; Deferasirox; Female; Ferritins; Glomerular Filtration Rate; Hemodynamics; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Circulation; Transfusion Reaction; Triazoles; Young Adult	2015
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. European journal of haematology, 2015, Volume: 95, Issue:5 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Pyridones; Severity of Illness Index; Triazoles	2015
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration. Clinical therapeutics, 2015, Volume: 37, Issue:8 Topics: Adult; Benzoates; beta-Thalassemia; Chromatography, High Pressure Liquid; Deferasirox; Drug Administration Schedule; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles; Young Adult	2015
Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major. Hemoglobin, 2015, Volume: 39, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Cardiomyopathies; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Stroke Volume; Treatment Outcome; Triazoles; Ventricular Function, Left; Young Adult	2015
The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Annals of hematology, 2015, Volume: 94, Issue:12 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Male; Taiwan; Time Factors; Triazoles	2015
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatric blood & cancer, 2017, Volume: 64, Issue:1 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Combined Modality Therapy; Deferasirox; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Iron Overload; Male; Phlebotomy; Prognosis; Prospective Studies; Triazoles	2017
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. European journal of haematology, 2009, Volume: 82, Issue:6 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug-Related Side Effects and Adverse Reactions; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Pyridones; Treatment Outcome; Triazoles; Young Adult	2009
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. European journal of haematology, 2009, Volume: 82, Issue:6 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Treatment Outcome; Triazoles; Young Adult	2009
Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Annals of hematology, 2010, Volume: 89, Issue:4 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Triazoles; Young Adult	2010
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood, 2010, Mar-25, Volume: 115, Issue:12 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Myocardium; Prospective Studies; Triazoles; Young Adult	2010
Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:5 Topics: Adult; Animals; Area Under Curve; Arylsulfatases; Benzoates; beta-Thalassemia; Cells, Cultured; Deferasirox; Feces; Female; Glucuronidase; Glucuronides; Hepatocytes; Humans; Hydroxylation; Iron Chelating Agents; Iron Overload; Male; Molecular Structure; Rats; Spectrometry, Mass, Electrospray Ionization; Sulfuric Acid Esters; Transfusion Reaction; Triazoles; Young Adult	2010
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood, 2010, Jul-29, Volume: 116, Issue:4 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Metabolic Clearance Rate; Myocardium; Treatment Outcome; Triazoles; Young Adult	2010
Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta haematologica, 2010, Volume: 123, Issue:4 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle East; Patient Satisfaction; Prospective Studies; Triazoles	2010
Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major. Pediatric hematology and oncology, 2010, Volume: 27, Issue:5 Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Benzoates; beta-Thalassemia; Bone Marrow Transplantation; Child; Child, Preschool; Creatine; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles	2010
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia. Annals of hematology, 2011, Volume: 90, Issue:1 Topics: Adult; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Deferasirox; Down-Regulation; Female; Hemoglobin, Sickle; Heterozygote; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Middle Aged; Radiography; Triazoles	2011
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. American journal of hematology, 2010, Volume: 85, Issue:10 Topics: Benzoates; beta-Thalassemia; Cardiomyopathies; Chelation Therapy; Deferasirox; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Liver Diseases; Siderosis; Stroke Volume; Transfusion Reaction; Treatment Outcome; Triazoles	2010
Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. British journal of haematology, 2010, Volume: 151, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Magnetic Resonance Imaging; Male; Treatment Outcome; Triazoles; Young Adult	2010
Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica, 2011, Volume: 96, Issue:7 Topics: Benzoates; beta-Thalassemia; Deferasirox; Ferritins; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Prognosis; Treatment Outcome; Triazoles	2011
The impact of two different doses of chelating therapy (deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major. European journal of haematology, 2011, Volume: 87, Issue:3 Topics: Adolescent; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Hemodynamics; Humans; Male; Triazoles; Young Adult	2011
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 2011, Jul-28, Volume: 118, Issue:4 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Deferoxamine; Female; Follow-Up Studies; Growth and Development; Humans; Iron; Iron Chelating Agents; Male; Middle Aged; Triazoles; Young Adult	2011
Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study. European journal of haematology, 2011, Volume: 87, Issue:4 Topics: Adolescent; Benzoates; beta-Thalassemia; Body Burden; Child; Child, Preschool; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Male; Prospective Studies; Triazoles	2011
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology, 2011, Volume: 141, Issue:4 Topics: Adolescent; Adult; Alanine Transaminase; Benzoates; beta-Thalassemia; Biomarkers; Biopsy; Child; Child, Preschool; Cross-Over Studies; Deferasirox; Female; Ferritins; Hepatitis C; Humans; Iron; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors; Treatment Outcome; Triazoles; Young Adult	2011
[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2011, Volume: 13, Issue:7 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Dose-Response Relationship, Drug; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles	2011
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica, 2012, Volume: 97, Issue:6 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Chelation Therapy; Child; Deferasirox; Drug Administration Schedule; Heart; Humans; Iron; Iron Chelating Agents; Iron Overload; Longitudinal Studies; Magnetic Resonance Angiography; Triazoles	2012
Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Annals of hematology, 2012, Volume: 91, Issue:9 Topics: Adult; Benzoates; beta-Thalassemia; Comorbidity; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Iron Chelating Agents; Male; Myocardium; Patient Compliance; Prospective Studies; Pyridones; Stroke Volume; Triazoles; Young Adult	2012
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica, 2013, Volume: 98, Issue:1 Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Male; Triazoles	2013
The effects of chelators on zinc levels in patients with thalassemia major. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2013, Volume: 27, Issue:2 Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Demography; Female; Humans; Iron Chelating Agents; Male; Pyridones; Triazoles; Young Adult; Zinc	2013
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (London, England), 2003, May-10, Volume: 361, Issue:9369 Topics: Adolescent; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Ferritins; Humans; Intestinal Absorption; Iron; Iron Overload; Male; Triazoles	2003
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. Journal of clinical pharmacology, 2003, Volume: 43, Issue:6 Topics: Administration, Oral; Adult; Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Double-Blind Method; Half-Life; Humans; Iron; Iron Chelating Agents; Male; Safety; Triazoles	2003
Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Dose-Response Relationship, Drug; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Transfusion Reaction; Treatment Outcome; Triazoles	2005
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, May-01, Volume: 107, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Drug Administration Schedule; Female; Humans; Iron; Iron Chelating Agents; Liver; Male; Middle Aged; Safety; Triazoles	2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, Volume: 91, Issue:7 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Transfusion Reaction; Treatment Outcome; Triazoles	2006
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 2006, Volume: 91, Issue:10 Topics: Administration, Oral; Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Drug Administration Schedule; Female; Humans; Iron Chelating Agents; Male; Triazoles	2006
Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:14 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Siderophores; Triazoles	2006
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clinical therapeutics, 2007, Volume: 29, Issue:5 Topics: Adolescent; Adult; Antidotes; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Deferoxamine; Female; Humans; Iron Overload; Male; Middle Aged; Prospective Studies; Treatment Outcome; Triazoles	2007
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood, 2008, Jan-15, Volume: 111, Issue:2 Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Deferoxamine; Erythrocyte Transfusion; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Liver; Male; Splenectomy; Triazoles	2008
Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy. Haematologica, 2008, Volume: 93, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Cataract; Child; Child, Preschool; Deferasirox; Humans; Iron Chelating Agents; Italy; Time Factors; Triazoles	2008
Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. British journal of haematology, 2008, Volume: 141, Issue:5 Topics: Adolescent; Adult; Arteries; Benzoates; beta-Thalassemia; Brachial Artery; Carotid Arteries; Deferasirox; Elasticity; Endothelium, Vascular; Female; Ferritins; Follow-Up Studies; Humans; Iron Chelating Agents; Male; Triazoles; Vasodilation; Ventricular Function, Left	2008
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica, 2008, Volume: 93, Issue:6 Topics: Adolescent; Adult; Ascorbic Acid; Benzoates; beta-Thalassemia; C-Reactive Protein; Child; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Lipid Peroxidation; Male; Oxidants; Oxidative Stress; Triazoles; Vitamin E	2008

Other Studies

97 other study(ies) available for triazoles and Anemia, Cooley's

Article	Year
Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major. Vox sanguinis, 2022, Volume: 117, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Retrospective Studies; Triazoles	2022
Nephrolithiasis in two patients on iron chelation therapy: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2023, Volume: 62, Issue:3 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Nephrolithiasis; Triazoles	2023
Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatrics international : official journal of the Japan Pediatric Society, 2021, Volume: 63, Issue:4 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Thalassemia; Triazoles	2021
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multi-center nation-wide cohort. Haematologica, 2022, 02-01, Volume: 107, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Risk Assessment; Risk Factors; Thalassemia; Triazoles	2022
Outcome of iron reduction therapy in ex-thalassemics. PloS one, 2021, Volume: 16, Issue:1 Topics: Adolescent; Allografts; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Iron; Iron Chelating Agents; Iron Overload; Male; Phlebotomy; Triazoles	2021
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran. Hemoglobin, 2021, Volume: 45, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iran; Iron Chelating Agents; Iron Overload; Male; Pyridones; Retrospective Studies; Thalassemia; Triazoles; Young Adult; Zinc	2021
Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya. Journal of basic and clinical physiology and pharmacology, 2021, Jun-25, Volume: 32, Issue:4 Topics: Adult; Benzoates; beta-Thalassemia; Costs and Cost Analysis; Deferasirox; Deferiprone; Drug Utilization; Ferritins; Hospitals, General; Humans; Iron Chelating Agents; Pharmaceutical Preparations; Retrospective Studies; Triazoles	2021
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load	2017
Pregnancy Outcome among Women with Beta-Thalassemia Major in North Sardinia. Acta haematologica, 2017, Volume: 138, Issue:3 Topics: Abortion, Spontaneous; Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Diabetes, Gestational; Female; Fetal Growth Retardation; Humans; Iron Chelating Agents; Italy; Pregnancy; Pregnancy Outcome; Premature Birth; Triazoles	2017
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. Pharmacogenetics and genomics, 2018, Volume: 28, Issue:1 Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Male; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Regression Analysis; Triazoles; Vitamin D; Vitamin D3 24-Hydroxylase	2018
Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients. Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:9 Topics: Benzoates; beta-Thalassemia; Deferasirox; Dialysis Solutions; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Treatment Outcome; Triazoles	2018
Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. British journal of haematology, 2013, Volume: 161, Issue:6 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Disease Management; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Italy; Liver; Male; Pyridones; Software; Triazoles; Young Adult	2013
Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters. Annals of hematology, 2014, Volume: 93, Issue:3 Topics: Adult; Aging; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Disease Susceptibility; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Incidence; Iron Chelating Agents; Iron Overload; Italy; Kidney; Male; Nephrolithiasis; Retrospective Studies; Transfusion Reaction; Triazoles; Ultrasonography	2014
Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Transfusion, 2014, Volume: 54, Issue:3 Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Triazoles	2014
Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature. Journal of clinical pharmacy and therapeutics, 2013, Volume: 38, Issue:6 Topics: Acidosis; Acidosis, Renal Tubular; Adolescent; Benzoates; beta-Thalassemia; Chlorine; Deferasirox; Female; Humans; Iron Chelating Agents; Triazoles	2013
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adult; Area Under Curve; Arrhythmias, Cardiac; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Patient Compliance; Predictive Value of Tests; Pyridones; Risk; ROC Curve; Sampling Studies; Transfusion Reaction; Triazoles; Young Adult	2013
Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology (Amsterdam, Netherlands), 2014, Volume: 19, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferoxamine; Female; Humans; Infant; Injections; Iron Chelating Agents; Male; Patient Compliance; Personal Satisfaction; Triazoles; Young Adult	2014
Laboratory investigation of platelet function in patients with thalassaemia. Acta haematologica, 2014, Volume: 132, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Platelets; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyridones; Triazoles; Young Adult	2014
Bad liver and a broken heart. Blood, 2014, Mar-06, Volume: 123, Issue:10 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferoxamine; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Myocardium; Triazoles	2014
Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Blood cells, molecules & diseases, 2014, Volume: 53, Issue:3 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overload; Male; Treatment Outcome; Triazoles	2014
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Adolescent; Alkalosis; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Diseases; Kidney Tubules; Male; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles; Water-Electrolyte Imbalance; Young Adult	2014
Immunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2014, Volume: 24, Issue:7 Topics: Adolescent; Adult; Age Distribution; Antibodies, Antinuclear; Benzoates; beta-Thalassemia; Blood Transfusion; Case-Control Studies; Deferasirox; Female; Ferritins; Humans; Immunoglobulin G; Incidence; Iron Chelating Agents; Lymphocytes; Male; Middle Aged; Saudi Arabia; Splenectomy; Triazoles	2014
Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among jordanian adolescents with Thalassemia major. Pediatric hematology and oncology, 2014, Volume: 31, Issue:7 Topics: Adolescent; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Cross-Sectional Studies; Deferasirox; Female; Ferritins; Follow-Up Studies; Humans; Male; Patient Compliance; Triazoles	2014
A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. Annals of hematology, 2015, Volume: 94, Issue:6 Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Myocardium; Treatment Outcome; Triazoles	2015
Thalassemia major patients using iron chelators showed a reduced plasma thioredoxin level and reduced thioredoxin reductase activity, despite elevated oxidative stress. Free radical research, 2015, Volume: 49, Issue:3 Topics: Adolescent; Adult; Antioxidants; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Female; Glutathione Transferase; Humans; Iron Chelating Agents; Male; Oxidative Stress; Oxidoreductases; Peroxiredoxins; Pyridones; Thioredoxin Reductase 1; Thioredoxins; Triazoles; Young Adult	2015
Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources. Transfusion medicine (Oxford, England), 2015, Volume: 25, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferoxamine; Developing Countries; Drug Therapy, Combination; Female; Ferritins; Humans; Iran; Lebanon; Male; Siderophores; Triazoles	2015
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study. Pediatric blood & cancer, 2015, Volume: 62, Issue:9 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Eruptions; Drug Therapy, Combination; Female; Ferritins; Gastrointestinal Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Joint Diseases; Male; Prospective Studies; Proteinuria; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2015
GFR in Patients with β-Thalassemia Major. Clinical journal of the American Society of Nephrology : CJASN, 2015, Aug-07, Volume: 10, Issue:8 Topics: Adult; Benzoates; beta-Thalassemia; Biomarkers; Creatinine; Deferasirox; Female; Glomerular Filtration Rate; Humans; Inulin; Iron Chelating Agents; Israel; Kidney; Kidney Diseases; Male; Models, Biological; Outpatient Clinics, Hospital; Predictive Value of Tests; Reproducibility of Results; Transfusion Reaction; Triazoles; Young Adult	2015
Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia. Hemoglobin, 2015, Volume: 39, Issue:5 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles; Young Adult	2015
Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators. Biological trace element research, 2016, Volume: 170, Issue:1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Female; Humans; Iron; Iron Chelating Agents; Male; Minerals; Pyridones; Triazoles; Young Adult	2016
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Infectious disorders drug targets, 2015, Volume: 15, Issue:2 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Pyridones; Triazoles	2015
Sensorineural hearing loss in β-thalassemia patients treated with iron chelation. Ear, nose, & throat journal, 2015, Volume: 94, Issue:12 Topics: Adolescent; Adult; Audiometry, Pure-Tone; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Female; Hearing Loss, Sensorineural; Humans; Iron Chelating Agents; Male; Middle Aged; Pyridones; Triazoles; Young Adult	2015
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? International journal of hematology, 2016, Volume: 103, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Female; Fetus; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pyridones; Triazoles	2016
Deferasirox and children: From clinical trials to the real world. American journal of hematology, 2016, Volume: 91, Issue:6 Topics: Age Factors; Benzoates; beta-Thalassemia; Child; Clinical Trials as Topic; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Transfusion Reaction; Treatment Outcome; Triazoles	2016
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypogonadism; Hypothyroidism; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Osteoporosis; Prevalence; Pyridones; Retrospective Studies; Transfusion Reaction; Triazoles	2016
Deferasirox AUC efficacy cutoff and role of pharmacogenetics. European journal of clinical pharmacology, 2016, Volume: 72, Issue:9 Topics: Area Under Curve; Benzoates; beta-Thalassemia; Deferasirox; Female; Genotype; Humans; Iron Chelating Agents; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome; Triazoles	2016
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients. The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:5 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Treatment Outcome; Triazoles	2017
Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:3 Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Fanconi Syndrome; Female; Humans; Liver Failure, Acute; Triazoles	2017
Evaluation of Proteinuria in β-Thalassemia Major Patients With and Without Diabetes Mellitus Taking Deferasirox. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Creatinine; Cross-Sectional Studies; Deferasirox; Deferiprone; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Proteinuria; Pyridones; Transfusion Reaction; Triazoles; Young Adult	2017
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:11 Topics: Adult; Area Under Curve; Benzoates; beta-Thalassemia; Biomarkers; Chromatography, High Pressure Liquid; Creatinine; Deferasirox; Drug Monitoring; Female; Ferritins; Half-Life; Humans; Iron Chelating Agents; Male; Spectrophotometry, Ultraviolet; Triazoles	2016
Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2017, Volume: 28, Issue:2 Topics: Benzoates; beta-Thalassemia; Child, Preschool; Deferasirox; Desensitization, Immunologic; Female; Humans; Iron Chelating Agents; Triazoles	2017
The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation. Hematology (Amsterdam, Netherlands), 2017, Volume: 22, Issue:4 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Humans; Male; Proteinuria; Retrospective Studies; Triazoles; Young Adult	2017
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 84 Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Hemochromatosis; Humans; Iron Chelating Agents; Middle Aged; Triazoles	2016
Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major. Therapeutic drug monitoring, 2017, Volume: 39, Issue:2 Topics: Adolescent; Adult; Amino Acids; Benzoates; beta-Thalassemia; Deferasirox; Drug Monitoring; Female; Humans; Iron; Iron Chelating Agents; Liver; Male; Triazoles; Young Adult	2017
Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clinical drug investigation, 2017, Volume: 37, Issue:5 Topics: Benzoates; beta-Thalassemia; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Routes; Health Care Costs; Humans; Iron Chelating Agents; Italy; Pyridones; Treatment Outcome; Triazoles	2017
Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With β-Thalassemia Major: An Experience From North India. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:3 Topics: Adolescent; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; India; Iron Chelating Agents; Kidney Function Tests; Liver Function Tests; Male; Prospective Studies; Pyridones; Tertiary Care Centers; Triazoles	2017
Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10. Haematologica, 2008, Volume: 93, Issue:6 Topics: Benzoates; beta-Thalassemia; Cataract; Deferasirox; Humans; Iron Chelating Agents; Research Design; Sample Size; Triazoles	2008
Iron and hepatitis C: what can we learn from thalassemia major? Liver international : official journal of the International Association for the Study of the Liver, 2008, Volume: 28, Issue:6 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Female; Ferritins; Hepacivirus; Hepatitis C, Chronic; Humans; Iron; Iron Deficiencies; Male; Phlebotomy; Siderophores; Triazoles	2008
Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia. Pediatric blood & cancer, 2009, Volume: 52, Issue:3 Topics: Adolescent; Benzoates; beta-Thalassemia; Cardiomyopathy, Dilated; Deferasirox; Humans; Iron; Male; Triazoles	2009
The effects of deferiprone and deferasirox on the structure and function of beta-thalassemia hemoglobin. Journal of biomolecular structure & dynamics, 2009, Volume: 27, Issue:3 Topics: Benzoates; beta-Thalassemia; Circular Dichroism; Deferasirox; Deferiprone; Hemoglobins; Humans; Iron Chelating Agents; Pyridones; Spectrometry, Fluorescence; Structure-Activity Relationship; Triazoles	2009
Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Bone Marrow Transplantation; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic; Combined Modality Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Guidelines as Topic; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Pyridones; Siderophores; Siderosis; Taiwan; Treatment Outcome; Triazoles	2009
Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. British journal of haematology, 2010, Volume: 148, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Ferritins; Heart; Humans; Iron Chelating Agents; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Pilot Projects; Prospective Studies; Treatment Outcome; Triazoles	2010
Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta haematologica, 2010, Volume: 123, Issue:1 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Deferoxamine; Erythrocytes; Erythroid Cells; Ferritins; Flow Cytometry; Humans; In Vitro Techniques; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Phosphatidylserines; Pyridones; Reactive Oxygen Species; Reticulocytes; Triazoles	2010
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:1 Topics: Acidosis; Benzoates; beta-Thalassemia; Chlorides; Deferasirox; Female; Humans; Iron Chelating Agents; Middle Aged; Triazoles	2010
Gastric ulcer in a child treated with deferasirox. Pharmacy world & science : PWS, 2010, Volume: 32, Issue:2 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Humans; Iron Chelating Agents; Stomach Ulcer; Triazoles	2010
Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy. Acta haematologica, 2010, Volume: 123, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles	2010
Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood cells, molecules & diseases, 2010, Mar-15, Volume: 44, Issue:3 Topics: Acute-Phase Proteins; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Cystatin C; Deferasirox; Female; Glomerular Filtration Rate; Humans; Iron Chelating Agents; Lipocalin-2; Lipocalins; Male; Natriuretic Peptide, Brain; Peptide Fragments; Proto-Oncogene Proteins; Triazoles; Young Adult	2010
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta haematologica, 2010, Volume: 123, Issue:3 Topics: Adolescent; Adult; Benzoates; beta 2-Microglobulin; beta-Thalassemia; Biomarkers; Chelation Therapy; Child; Child, Preschool; Cystatin C; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Early Diagnosis; Female; Humans; Hypercalciuria; Iron Chelating Agents; Kidney Diseases; Kidney Function Tests; Male; Proteinuria; Pyridones; Triazoles; Young Adult	2010
Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI. Clinical drug investigation, 2010, Volume: 30, Issue:4 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Deferasirox; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Myocardium; Time Factors; Triazoles; Ventricular Function, Left; Young Adult	2010
Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. American journal of hematology, 2010, Volume: 85, Issue:6 Topics: Administration, Oral; Arthralgia; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Iron Chelating Agents; Iron Overload; Pyridones; Transfusion Reaction; Triazoles; Young Adult	2010
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. European journal of haematology, 2010, Volume: 85, Issue:4 Topics: Adolescent; Adult; Age Factors; Benzoates; beta-Thalassemia; Child; Death; Deferasirox; Deferiprone; Deferoxamine; Female; Greece; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Spectroscopy; Male; Pyridones; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2010
Deferasirox use after hematopoietic stem cell transplantation in pediatric patients with beta-thalassemia major: preliminary results. Pediatric hematology and oncology, 2010, Volume: 27, Issue:6 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance Imaging; Male; Treatment Outcome; Triazoles	2010
Deferasirox--current knowledge and future challenges. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Ferritins; Humans; Iron; Iron Chelating Agents; Myocardium; Triazoles	2010
Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:7 Topics: Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Combined Modality Therapy; Deferasirox; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Kidney Tubules, Proximal; Male; Triazoles; Water-Electrolyte Imbalance	2010
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2011, Volume: 96, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyridones; Retrospective Studies; Siderophores; Triazoles; Ventricular Function; Young Adult	2011
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica, 2011, Volume: 96, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Male; Middle Aged; Myocardium; Prognosis; Prospective Studies; Triazoles; Ventricular Function, Left; Young Adult	2011
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Pediatric blood & cancer, 2011, Volume: 56, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Maximum Tolerated Dose; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult	2011
Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion, 2011, Volume: 51, Issue:5 Topics: Adolescent; Benzoates; beta-Thalassemia; Deferasirox; Fanconi Syndrome; Hospitalization; Humans; Iron Chelating Agents; Iron Overload; Kidney; Male; Transfusion Reaction; Triazoles	2011
The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results. Pediatric hematology and oncology, 2011, Volume: 28, Issue:3 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Deferasirox; Female; Heart; Humans; Iron Chelating Agents; Iron Overload; Kidney; Liver; Male; Prospective Studies; Treatment Outcome; Triazoles; Young Adult	2011
Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:4 Topics: Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Death; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Egypt; Electrocardiography; Female; Ferritins; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridones; Sex Factors; Siderophores; Siderosis; Triazoles	2010
Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®). European journal of haematology, 2011, Volume: 86, Issue:3 Topics: Adult; Benzoates; beta-Thalassemia; Contraindications; Deferasirox; Female; Humans; Infant, Newborn; Iron Chelating Agents; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Triazoles	2011
Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major. Annals of tropical paediatrics, 2011, Volume: 31, Issue:1 Topics: Adolescent; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Female; Humans; India; Iron Chelating Agents; Iron Overload; Male; Transfusion Reaction; Triazoles	2011
A case of well-tolerated and safe deferasirox administration during the first trimester of a spontaneous pregnancy in an advanced maternal age thalassemic patient. Acta haematologica, 2011, Volume: 125, Issue:4 Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Maternal Age; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, First; Triazoles	2011
Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatric blood & cancer, 2011, Volume: 56, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Erythrocyte Transfusion; Fanconi Syndrome; Female; Humans; Iron Chelating Agents; Iron Overload; Male; Triazoles	2011
Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia? Angiology, 2011, Volume: 62, Issue:4 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Fatal Outcome; Humans; Iron Chelating Agents; Male; Multiple Organ Failure; Risk Factors; Triazoles	2011
Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. British journal of haematology, 2011, Volume: 154, Issue:5 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Treatment Outcome; Triazoles	2011
Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clinical drug investigation, 2011, Volume: 31, Issue:7 Topics: Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Health Care Costs; Humans; Iron Chelating Agents; Markov Chains; Models, Economic; Pyridones; Quality-Adjusted Life Years; Thailand; Triazoles	2011
Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. European journal of haematology, 2011, Volume: 87, Issue:4 Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Triazoles	2011
Absence of teratogenicity of deferasirox treatment during pregnancy in a thalassaemic patient. Pediatric endocrinology reviews : PER, 2011, Volume: 8 Suppl 2 Topics: Adult; Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Infant, Newborn; Iron Chelating Agents; Male; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Teratogens; Triazoles	2011
Chelation therapy for secondary iron overload: is the primary effect less iron or less liver fibrosis? Gastroenterology, 2011, Volume: 141, Issue:4 Topics: Benzoates; beta-Thalassemia; Deferasirox; Female; Humans; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Triazoles	2011
Challenges of adherence and persistence with iron chelation therapy. International journal of hematology, 2011, Volume: 94, Issue:5 Topics: Administration, Oral; Adolescent; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Deferoxamine; Dosage Forms; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Patient Care Team; Patient Compliance; Pyridones; Time Factors; Triazoles	2011
Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report. Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:1 Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; Benzoates; beta-Thalassemia; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Male; Triazoles	2012
Hydrophilic interaction liquid chromatography/positive ion electrospray mass spectrometry for the quantification of deferasirox, an oral iron chelator, in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Apr-15, Volume: 893-894 Topics: Acetates; Acetonitriles; Adult; Benzoates; beta-Thalassemia; Chromatography, Liquid; Deferasirox; Female; Humans; Hydrophobic and Hydrophilic Interactions; Linear Models; Male; Methanol; Mianserin; Mirtazapine; Spectrometry, Mass, Electrospray Ionization; Triazoles	2012
Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy. Hemoglobin, 2012, Volume: 36, Issue:3 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron Chelating Agents; Male; Pyridones; Treatment Outcome; Triazoles; Ubiquinone; Young Adult	2012
Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Female; Greece; Humans; Hypercalciuria; Hyperuricemia; Iron Chelating Agents; Iron Overload; Male; Nephrolithiasis; Postoperative Complications; Pyridones; Splenectomy; Transfusion Reaction; Triazoles; Young Adult	2013
Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. Clinical drug investigation, 2012, Volume: 32, Issue:12 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cohort Studies; Cost-Benefit Analysis; Deferasirox; Deferoxamine; Drug Costs; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Overload; Medication Adherence; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Triazoles; United Kingdom	2012
Successful treatment of Trichosporon asahii infection with voriconazole after bone marrow transplant. Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:3 Topics: Antifungal Agents; beta-Thalassemia; Bone Marrow Transplantation; Child; Humans; Male; Prognosis; Pyrimidines; Triazoles; Trichosporon; Trichosporonosis; Voriconazole	2013
Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients. Transfusion, 2013, Volume: 53, Issue:8 Topics: Administration, Oral; Adult; Benzoates; beta-Thalassemia; Cost-Benefit Analysis; Cross-Sectional Studies; Deferasirox; Deferoxamine; Drug Costs; Female; Humans; Infusions, Intravenous; Iran; Iron Chelating Agents; Iron Overload; Male; Markov Chains; Models, Economic; Quality-Adjusted Life Years; Transfusion Reaction; Treatment Outcome; Triazoles	2013
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major. Haematologica, 2013, Volume: 98, Issue:4 Topics: Adult; Benzoates; beta-Thalassemia; Blood Cell Count; Chelation Therapy; Colony-Forming Units Assay; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine; Erythroid Precursor Cells; Female; Ferritins; Flow Cytometry; Hematopoietic Stem Cells; Humans; Iron Chelating Agents; Linear Models; Male; Multivariate Analysis; Myeloid Progenitor Cells; Pyridones; Splenectomy; Triazoles; Young Adult	2013
Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:1 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Middle Aged; Pyridones; Retrospective Studies; Splenectomy; Triazoles; Young Adult	2013
Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience. Pediatric hematology and oncology, 2013, Volume: 30, Issue:2 Topics: Administration, Oral; Adolescent; Age Factors; Benzoates; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; Deferiprone; Female; Ferritins; Humans; Infant; Iron Chelating Agents; Male; Pyridones; Retrospective Studies; Triazoles; Vitamin D Deficiency	2013
ICL670A: preclinical profile. Advances in experimental medicine and biology, 2002, Volume: 509 Topics: Administration, Oral; Animals; Benzoates; beta-Thalassemia; Callithrix; Deferasirox; Dogs; Drug Evaluation, Preclinical; Drug Tolerance; Humans; Iron; Iron Chelating Agents; Iron Overload; Molecular Structure; Rats; Triazoles	2002
Iron chelation therapy. Current hematology reports, 2005, Volume: 4, Issue:2 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver Injury; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Iron Chelating Agents; Iron Overload; Isoniazid; Pyridones; Pyridoxal; Survival; Triazoles	2005
Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. PharmacoEconomics, 2007, Volume: 25, Issue:4 Topics: Administration, Oral; Benzoates; beta-Thalassemia; Blood Transfusion; Cost-Benefit Analysis; Deferasirox; Delivery of Health Care; Drug Administration Schedule; Drug Utilization Review; Economics, Pharmaceutical; Humans; Infusions, Intravenous; Insurance Claim Review; Iron Chelating Agents; Iron Overload; Markov Chains; Treatment Outcome; Triazoles; United States	2007
[Post transfusionnal iron overload]. La Revue du praticien, 2006, Dec-15, Volume: 56, Issue:19 Topics: Benzoates; beta-Thalassemia; Deferasirox; Deferiprone; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Magnetic Resonance Imaging; Pyridones; Randomized Controlled Trials as Topic; Triazoles	2006
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European journal of haematology, 2008, Volume: 80, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Diamond-Blackfan; Benzoates; beta-Thalassemia; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Thalassemia; Treatment Outcome; Triazoles	2008
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, Volume: 93, Issue:5 Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Child; Decision Support Techniques; Deferasirox; Deferiprone; Deferoxamine; Hematology; Humans; Iron Chelating Agents; Iron Overload; Liver; Practice Guidelines as Topic; Pyridones; Siderophores; Triazoles	2008